EE04047B1 - Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid - Google Patents

Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid

Info

Publication number
EE04047B1
EE04047B1 EE9700240A EE9700240A EE04047B1 EE 04047 B1 EE04047 B1 EE 04047B1 EE 9700240 A EE9700240 A EE 9700240A EE 9700240 A EE9700240 A EE 9700240A EE 04047 B1 EE04047 B1 EE 04047B1
Authority
EE
Estonia
Prior art keywords
ftc
zidovudine
synergistic combinations
synergistic
combinations
Prior art date
Application number
EE9700240A
Other languages
English (en)
Estonian (et)
Other versions
EE9700240A (et
Inventor
Walter Barry David
Heider St. Clair Martha
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04047(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Publication of EE9700240A publication Critical patent/EE9700240A/xx
Publication of EE04047B1 publication Critical patent/EE04047B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Cephalosporin Compounds (AREA)
EE9700240A 1995-03-30 1996-03-28 Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid EE04047B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (2)

Publication Number Publication Date
EE9700240A EE9700240A (et) 1998-04-15
EE04047B1 true EE04047B1 (et) 2003-06-16

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700240A EE04047B1 (et) 1995-03-30 1996-03-28 Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid

Country Status (35)

Country Link
US (1) US6417191B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0817637B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2954357B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100542536B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1103593C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP652A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE220551T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU715213B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (3) BR9607851B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2216634C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ295940B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE122005000029I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0817637T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA000626B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE04047B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2179193T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR05C0022I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP20022647B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU224010B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL117727A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91171I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9707316A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY115461A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300195I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO313787B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ306419A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA10616A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL187085B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT817637E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO117995B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI0817637T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK283825B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR199701074T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA60293C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1996030025A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127351A0 (en) 1996-06-25 1999-10-28 Glaxo Group Ltd Combinations comprising VX478 zidovudine FTC and/or 3TC for use in the treatment of HIV
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
CA2289655A1 (en) * 1997-05-17 1998-11-26 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
CA2374198A1 (en) * 1998-05-29 1999-12-02 Maki Arai Combination therapy for treatment of fiv infection
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
CA2512319A1 (en) 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
DK1692516T3 (da) 2003-10-24 2011-02-28 Immunaid Pty Ltd Terapifremgangsmåde
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
JP2009515826A (ja) 2005-10-19 2009-04-16 エフ.ホフマン−ラ ロシュ アーゲー フェニル−アセトアミドnnrt阻害剤
CN101553483B (zh) 2006-12-13 2013-04-17 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的2-(哌啶-4-基)-4-苯氧基-或苯基氨基-嘧啶衍生物
NZ599031A (en) * 2007-02-09 2013-11-29 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
US9122778B2 (en) 2009-05-27 2015-09-01 Biotempus Limited Methods of treating diseases
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
CA2918707A1 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
WO2015155673A1 (en) 2014-04-08 2015-10-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
US11311512B2 (en) 2014-08-12 2022-04-26 Monash University Lymph directing prodrugs
CN118063537A (zh) 2015-09-08 2024-05-24 莫纳什大学 定向淋巴的前药
WO2019046491A1 (en) * 2017-08-29 2019-03-07 Ariya Therapeutics, Inc. LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
WO2021159021A1 (en) 2020-02-05 2021-08-12 Puretech Lyt, Inc. Lipid prodrugs of neurosteroids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
AU1787492A (en) * 1991-05-16 1992-12-30 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
EP0639971B1 (en) * 1992-05-13 1999-09-22 The Wellcome Foundation Limited Therapeutic combinations
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
ES2189964T3 (es) 1996-06-25 2003-07-16 Glaxo Group Ltd Combinaciones que comprenden vx478, zidovudina, y 1592u89 para uso en el tratamiento de infecciones por vih.
IL127351A0 (en) 1996-06-25 1999-10-28 Glaxo Group Ltd Combinations comprising VX478 zidovudine FTC and/or 3TC for use in the treatment of HIV
DE10226522A1 (de) 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
DE122005000029I1 (de) 2005-10-06
NO2005014I1 (no) 2005-06-06
DE69622386D1 (de) 2002-08-22
NO2005014I2 (no) 2008-02-11
DE69622386T2 (de) 2003-02-13
EP0817637B1 (en) 2002-07-17
CZ309097A3 (cs) 1998-05-13
FR05C0022I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2005-10-21
JP2954357B2 (ja) 1999-09-27
BRPI9607851B8 (pt) 2019-11-05
SK283825B6 (sk) 2004-02-03
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
AP9701089A0 (en) 1997-10-31
HU224010B1 (hu) 2005-04-28
AU715213B2 (en) 2000-01-20
SK129597A3 (en) 1998-07-08
JPH10511682A (ja) 1998-11-10
EA000626B3 (ru) 2016-04-29
OA10616A (en) 2001-03-15
ES2179193T3 (es) 2003-01-16
UA60293C2 (uk) 2003-10-15
BR9607851B1 (pt) 2009-01-13
PL187085B1 (pl) 2004-05-31
NL300195I2 (nl) 2005-11-01
LU91171I2 (fr) 2005-07-04
NO974510D0 (no) 1997-09-29
AP652A (en) 1998-06-19
EP0817637A1 (en) 1998-01-14
HUP9801571A2 (hu) 1999-01-28
GEP20022647B (en) 2002-03-25
BRPI9612992B1 (pt) 2020-08-04
EA000626B1 (ru) 1999-12-29
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
EE9700240A (et) 1998-04-15
WO1996030025A1 (en) 1996-10-03
AU5497296A (en) 1996-10-16
US6417191B1 (en) 2002-07-09
CZ295940B6 (cs) 2005-12-14
CA2216634C (en) 2004-07-20
IL117727A0 (en) 1996-07-23
MY115461A (en) 2003-06-30
NO313787B1 (no) 2002-12-02
EA199700203A1 (ru) 1998-02-26
NO974510L (no) 1997-09-29
HK1009401A1 (en) 1999-09-10
LU91171I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-12-28
SI0817637T1 (en) 2002-10-31
MX9707316A (es) 1997-11-29
DE122005000029I2 (de) 2006-04-27
BR9607851A (pt) 1998-07-21
IL117727A (en) 1999-11-30
KR19980703420A (ko) 1998-11-05
CA2216634A1 (en) 1996-10-03
CN1103593C (zh) 2003-03-26
DK0817637T3 (da) 2002-11-11
PL322532A1 (en) 1998-02-02
KR100542536B1 (ko) 2006-03-23
CN1185110A (zh) 1998-06-17
HUP9801571A3 (en) 2001-04-28
ATE220551T1 (de) 2002-08-15
RO117995B1 (ro) 2002-12-30
FR05C0022I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2005-06-10

Similar Documents

Publication Publication Date Title
EE04047B1 (et) Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid
EE03741B1 (et) N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine
EE03427B1 (et) Pihusti sõlm ja selle kasutamine
DK0832104T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
FI964311L (fi) Bifunktionaalinen proteiini, valmistus ja käyttö
FI960889A7 (fi) Naftyyliyhdisteitä, välituotteita, koostumuksia ja menetelmiä
EE04500B1 (et) Trombiini inhibiitorid, nende saamine ja kasutamine
FI952158L (fi) Hiihtokäsine ja hihtosauva sekä niiden yhdistelmä
NO961721D0 (no) 2-oksetanon-limingsmidler, deres fremstilling og bruk
BR9611179A (pt) Composiç o em creme
DK0840548T3 (da) Synergistisk, herbicid sammensætning samt fremgangsmåde til fremstilling deraf
FI972988L (fi) Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
DK60893D0 (da) Piperidinderivater, deres fremstilling og anvendelse
EE9800451A (et) Uued imidasotriasolopürimidiinid, nende valmistamismeetod ja kasutamine ravimainetena
FI952738L (fi) Stabiiliproteiini, fosfolipidikoostumuksia ja menetelmiä
PT826679E (pt) Compostos de naftilo intermediarios composicoes e metodos de utilizacao
BR9610382A (pt) Composição de tratamento do cableo
FI972965A0 (fi) Uusia peptidejä, niiden valmistus ja käyttö
EE200000018A (et) 6-pürrolidiin-2-üülpüridiinid, nende valmistamine ja terapeutiline kasutamine
FI971872L (fi) Proteiinikoostumus ja sen valmistus ja käyttö sekä sitä sisältävät valmisteet ja näiden valmistus
NO972821D0 (no) 1-C-perfluoralkylglycosider, deres fremstilling og anvendelse
FI964446L (fi) Uusia tetrapeptidejä, niiden valmistus ja käyttö
PT101949A (pt) Boneco com elevacao simultania de bracos, pernas e abertura de olhos
FI942331L (fi) Biosidisia koostumuksia ja niiden käyttö
FI970497A0 (fi) Arrangemang foer raeddningsvaeg i en byggnad med flera vaoningar

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

FG1Y Spc granted

Free format text: PRODUCT NAME: KIVEXA; NAT. REGISTRATION NO/DATE: C(2004)5373 20041217; FIRST REGISTRATION: EU/1/04/298/001-002

Spc suppl protection certif: C20050002 00007

Filing date: 20050512

Extension date: 20191217

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

SPCM Correction and amendment to the data concerning application for a supplementary protection certificate

Spc suppl protection certif: C20050002 00007

Extension date: 20191222

SPCX Term of validity of supplementary protection expired

Spc suppl protection certif: 00007

Extension date: 20211209